推荐产品
方案
~98% (HPLC)
表单
solid
颜色
off-white
溶解性
DMSO: >10 mg/mL
H2O: insoluble
创始人
Roche
储存温度
2-8°C
SMILES字符串
CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C3CCC3)c1)C(O)=O
InChI
1S/C23H28N2O3S/c1-3-23(4-2,22(27)28)14-20(26)24-18-10-5-7-16(13-18)11-12-21-25-19(15-29-21)17-8-6-9-17/h5,7,10-13,15,17H,3-4,6,8-9,14H2,1-2H3,(H,24,26)(H,27,28)/b12-11+
InChI key
BZMKNPGKXJAIDV-VAWYXSNFSA-N
基因信息
human ... CYSLTR1(10800)
生化/生理作用
Specific CysLT1 leukotriene receptor antagonist.
特点和优势
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
H Maehr et al.
Bioorganic & medicinal chemistry, 5(3), 493-496 (1997-03-01)
Structure optimization of the leukotriene D4 antagonist Ro24-5913 was attempted by combinatorial chemistry. Three segments in its N-succinyl-3-(2-thiazolylethenyl)anilide skeleton, designated as A, B, and C coincided with the thiazolyl, aniline, and N-acyl moieties, respectively, and were selected for variations in
G E Rovati et al.
Biochemical pharmacology, 44(7), 1411-1415 (1992-10-06)
We have identified and characterized two different subclasses of binding site for the novel peptido-leukotriene (LT) antagonist, [3H]ICI 198,615, in membranes from human lung parenchyma using a receptor-ligand assay. This novel compound is representative of a new class of LT
Michael Föller et al.
European journal of clinical investigation, 40(6), 534-540 (2010-05-12)
Fever and hyperthermia are frequently associated with anaemia. Under most clinical conditions, they are considered to be two mutually independent clinical consequences of a common cause. The present study explored the possibility that anaemia results from temperature-sensitive suicidal erythrocyte death
Ro 24-5913: a potent, specific, orally active LTD4 antagonist.
M O'Donnell
Annals of the New York Academy of Sciences, 629, 413-415 (1991-01-01)
E Adelroth et al.
The Journal of allergy and clinical immunology, 99(2), 210-215 (1997-02-01)
The degree and duration of protection against exercise-induced bronchoconstriction afforded by three doses of a specific leukotriene D4 receptor antagonist, cinalukast, were assessed after an initial dosing and after 1 week of therapy. A placebo-controlled crossover study was performed in
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
Discover Bioactive Small Molecules for Lipid Signaling Research
Discover Bioactive Small Molecules for Lipid Signaling Research
Discover Bioactive Small Molecules for Lipid Signaling Research
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门